November 18, 2020

Short-term COVID Pain Versus Long-term Vaccine
Major Developments This Week

- Vaccine breakthrough by Pfizer/BioNTech and Moderna 90%+ effective.
- Economy and markets unconditionally dependent on vaccine ending the pandemic.
- Next few months economic growth rate likely to moderate, 2H 2021 outlook looks good.
- Stocks rallied to another record high based on earnings and vaccine prospects.
- 2021 earnings projected to be ~10% higher than all-time high earnings.
- Valuation of equities high and likely to remain so based on strong earnings growth, low interest rates.
- Jobs regained over the next year will likely bring unemployment from present 11 million to 9 million.
- Stimulus talks remain uncertain in timeline and amount and causing economic slowing.
- Gridlock is good.
- Monetary and fiscal policy decisions remain dominate forces to economic activity.
- COVID cases continue at high levels in USA and Europe.
- COVID hospitalizations and fatalities rising as well. Next few months challenging.

Source: CNR Research.
CNR Progress Playbook

**Investment Committee considering:**

- Despite negative COVID data, markets focused on unexpectedly good vaccine results.
- Transition of economy by mid-year 2021 to the post COVID normalcy.
- Equity emphasis shifting more broadly to non-pandemic driven businesses.
- Employment gains likely to pick up in 2H2021 supporting consumer spending.
- Stay fully committed to USA vs European equities.
- Staying focused on favorite themes in a return to normalcy, lower for longer interest rate world.
- Expect High Dividend equities to generate much better returns in 2021 vs 2020.
- Stay fully committed to High yield bonds, taxable and municipal.
- Underweight Investment grade bonds due to very low total returns.
- Potential for multi-year economy expansion ahead.
- Trillions searching for good returns remains untapped in consumer and business hands.

Source: CNR Research.
National Cases, Hospitalizations & Fatalities

- Hospitalizations have surpassed previous peak
- Increases widespread, but largest contribution from the Midwest

Hospitalization and fatality data source from the COVID Tracking Project and supplemented by estimated hospitalization data from IHME where no hospitalization data was officially reported.
Europe’s Surge Has Reached Prior Peak Levels

Europe: Cases and Fatalities

Source: European Centre for Disease Prevention and Control.
Targeted not Widespread Restrictions on Activity Expected

- So far, states have targeting indoor businesses and activities such as bars and restaurants
- A return to nationwide lockdowns is not expected at this point.

Where are States Tightening Restrictions?
(Change since Sept. 1)

- Workplace/restaurants/bars
- Social gathering sizes
- Stay-at-home orders
- Public events
- Public information campaigns
- School openings/closures

Source: University of Oxford.
Vaccines Expected to Become Widely Available by Spring

- Limited to high risk groups for 2-3 months, then expanded to broader population
- Adequate supply contingent on multiple vaccines being successful

U.S.: Potential Vaccine Supply Available

- December: ~5-10% of population
- January: ~10-15% of population
- February: ~20-30% of population
- March: ~40-50% of population
- April: ~65-75% of population
- May: ~100-110% of population
- June: ~120-140% of population

Source: CNR Research.
Consumer Spending Improvement Slows In The Short-term

- Near-term slowdown in consumer spending related to virus spread, local restrictions

Credit/Debit Card Spending (Rolling 7-Day Avg.)

Source: Affinity Solutions, Opportunity Insights.
Consumer Spending Expected To Improve Through 2021

- With vaccine on the way, decreases in consumer activity expected to be temporary
- Continued progress expected over the longer term

![Personal Consumption Expenditures Chart](chart)

Source: Bloomberg.
Income and Savings: Jobs vs. Stimulus

- Personal income has held up as unemployment benefits expire – improving jobs market
- More stimulus likely needed
- CARES year-end expirations: Extension need for enhanced unemployment benefits, eviction stays, loan forbearance

**Personal Income and Savings**

Source: Bloomberg.
European Restrictions Take Their Toll

- Tighter restrictions have weighed on mobility
- European consumer confidence expected to decline
Global Outlook Becoming More Divergent

- Euro outlook has darkened with 2nd waves prompting widespread restrictions and reduced fiscal support
- US looks more resilient, given sharper recovery and more targeted restrictions.
- China continues to lead global recovery, amid stimulus and relatively effective virus containment
U.S. and Emerging Markets Asia Continue to Outperform

- U.S. better positioned than Europe for short-term recovery and long-term economic growth
- Emerging markets in Asia present a more positive growth outlook than other emerging markets

Regional Equity Market Performance: 5 Years As of 10/31/2020

- U.S.: 12%
- Europe: 2%
- Emerging Markets Asia: 10%
- Emerging Markets excluding Asia: -3%

Stock Market Looking Ahead To Improved 2021 Earnings

- Earnings reports suggest a better-than expected recovery in corporate profits in 2020
- 2021 earnings expected to be above 2019 earnings

NDR Forecast Earnings Growth: 2020 and 2021

Source: CNR Research, NDR.
Framework For Portfolio Development to Achieve Goals

<table>
<thead>
<tr>
<th>Asset Mix</th>
<th>Stock &amp; Bond Strategy</th>
<th>Equity Mix</th>
<th>Large or Small Stocks, U.S. or International, Growth or Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock and Bond Selection</td>
<td>Rigorous Fundamental Research</td>
<td>Manager Selection</td>
<td>Separate Accounts and/or Funds</td>
</tr>
<tr>
<td>Portfolio Construction &amp; Management</td>
<td>Rebalancing, Tax Loss Harvesting, Timing</td>
<td><strong>Asset Allocation</strong> is the most critical initial step in the process of the <strong>Portfolio Construction</strong></td>
<td></td>
</tr>
</tbody>
</table>
Investment Universe – Prioritize Mindset to Goals

*Instead of Stocks & Bonds – Think of “Sources of Return” from all Asset Classes*

**PORTFOLIO POSITIONING**

**Dedicated Growth Strategies**
- U.S. Equities: Large and Mid/Small Cap
- International Equities: Developed and Emerging

**Growth and Income Strategies**
- High Dividend and Income Equities
- Opportunistic Income

**Safety of Principal**
- Core Fixed Income

**Alternative Investments**
- Income
- Growth/Total Return
- Diversification

*Achieving Goals in a Low Interest Rate Environment Requires Flexible Thinking*
Our Stock Selection Process

Industry Groups & Secular Themes

Attractive Companies

Valuation
Focusing on High Quality Stocks in Line with Five Key Themes

- High Quality
- Evolving Consumer
- Domestic Growers
- Industrial Leaders
- Healthcare Innovators
- Digital Revolution
- Sustainable Business Models
- Reasonable Valuations

Source: CNR Research.
# Core Equities: Pandemic Accelerated Long-Term Trends

<table>
<thead>
<tr>
<th>PORTFOLIO POSITIONING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evolving Consumer</td>
</tr>
<tr>
<td>- E-Commerce</td>
</tr>
<tr>
<td>- Home products and entertainment</td>
</tr>
<tr>
<td>Digital Revolution</td>
</tr>
<tr>
<td>- Software &amp; Services</td>
</tr>
<tr>
<td>- Telecom Services</td>
</tr>
<tr>
<td>Healthcare Innovators</td>
</tr>
<tr>
<td>- Healthcare Equipment</td>
</tr>
<tr>
<td>- Support of Drug Development</td>
</tr>
</tbody>
</table>

Source: CNR Research.
Pandemic Accelerated Long-term Trends

E-Commerce Sales as Percent of Total

Source: Bloomberg, U.S. Census Bureau.
Focus On High Quality Companies, Reasonable Valuations

- Speculative emerging technology stocks are unprofitable but highly valued
- Preference for established, profitable companies expected to benefit from key trends

**Profitability: Return on Equity**

**Valuations: Price to Earnings Ratio**

Source: CNR Research, Bloomberg.
Questions?
Important Information

The information presented does not involve the rendering of personalized investment, financial, legal, or tax advice. This presentation is not an offer to buy or sell, or a solicitation of any offer to buy or sell any of the securities mentioned herein.

The material contains forward-looking statements regarding intent, beliefs, or current expectations which are used for informational purposes only. Readers are cautioned that such forward-looking statements are not a guarantee of future performance, involve risks and uncertainties, and actual results may differ materially from those statements as a result of various factors. The views expressed are also subject to change based on market and other conditions. Furthermore, the opinions and information presented do not involve the rendering of personalized investment, financial, legal, or tax advice.

Investments in below-investment-grade debt securities which are usually called “high-yield” or “junk bonds,” are typically in weaker financial health and such securities can be harder to value and sell and their prices can be more volatile than more highly rated securities. While these securities generally have higher rates of interest, they also involve greater risk of default than do securities of a higher-quality rating.

Investing in international markets carries risks such as currency fluctuation, regulatory risks, economic and political instability. Emerging markets involve heightened risks related to the same factors as well as increased volatility, lower trading volume, and less liquidity. Emerging markets can have greater custodial and operational risks, and less developed legal and accounting systems than developed markets.

Certain information has been provided by third-party sources and, although believed to be reliable, it has not been independently verified and its accuracy or completeness cannot be guaranteed.

Adjustments to portfolio strategies are based on guidelines set forth by City National Rochdale’s Asset Allocation Committee. Individual client allocations among strategies, asset classes, portfolio weightings may be higher or lower given differences in portfolio holdings, client imposed restrictions, and/or the customized strategy implemented by each client’s portfolio manager. These differences may have a material impact on individual client’s performance returns.

Any opinions, projections, forecasts, and forward-looking statements presented herein are valid as on the date of this document and are subject to change.

This material is available to advisory and sub-advised clients, as well as financial professionals working with City National Rochdale, a registered investment advisor and a wholly-owned subsidiary of City National Bank.

Indices are unmanaged and one cannot invest directly in an index. Index returns do not reflect a deduction for fees or expenses. This material represents an assessment of the market environment at a specific point in time and is not intended to be a forecast of future events or a guarantee of future results.
Important Information

This presentation is for general information and education only. City National makes no representations or warranties in respect of this presentation and is not responsible for the accuracy, completeness or content of information contained in this presentation. City National is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained in or from the site. The information in this presentation should not be used to obtain credit or for any other commercial purpose nor should it be construed as tax, accounting, regulatory or legal advice. Rules in the areas of law, tax and accounting are subject to change and open to varying interpretations and you should seek professional advice from your advisor. Nothing in this presentation should be construed as an offer, or solicitation of an offer, to buy or sell any financial instrument. It should not be relied upon as specific investment advice directed to the viewer's specific investment objectives. Any financial instrument discussed in this presentation may not be suitable for the viewer. Each viewer must make his or her own investment decision, using an independent advisor if prudent, based on his or her own investment objective and financial situation. Prices and availability of financial instruments are subject to change without notice. Financial instruments denominated in a foreign currency are subject to exchange rate risk in addition to the risk of the investment. City National Bank (and its clients or associated persons) may, at times, engage in transactions in a manner inconsistent with this presentation and, with respect to particular securities and financial instruments discussed, may buy from or sell to clients or others on a principal basis. Past performance is not necessarily an indication of future results.

Alternative investments are speculative, entail substantial risks, offer limited or no liquidity and are not suitable for all investors. These investments have limited transparency to the funds’ investments and may involve leverage which magnifies both losses and gains, including the risk of loss of the entire investment. Alternative investments have varying, and lengthy lockup provisions.

The expected returns shown do not include fees for trading costs (e.g., commissions) or any fees charged by your financial advisor. Please speak to your financial advisor for a complete understanding of all fees.

Non-Deposit Investment Products:

- Are not insured by the FDIC.
- Are not deposits or other obligations of or guaranteed by City National Bank.
- Are subject to investment risks, including possible loss of the principal amount invested.

Deposit products and services are provided by City National Bank Member FDIC. City National Bank is a subsidiary of Royal Bank of Canada.

Redistributed with the permission of City National Rochdale.
**Index Definitions**

The Standard and Poor’s 500 Index (S&P 500) is a market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.

The S&P 500 Growth Index is a market capitalization weighted index. All the stocks in the underlying parent index are allocated into value or growth. Stocks that do not have pure value or pure growth characteristics have their market caps distributed between the value & growth indices. Prior to 12/19/2005 this index represented the S&P 500/Barra Growth Index.

The Dow Jones Select Dividend Index seeks to represent the top 100 U.S. stocks by dividend yield. The index is derived from the Dow Jones U.S. Index and generally consists of 100 dividend-paying stocks that have five-year non-negative Dividend Growth, five-year Dividend Payout Ratio of 60% or less, and three-month average daily trading volume of at least 200,000 shares.

The Bloomberg Barclays U.S. Corporate Bond Index is an unmanaged market-value-weighted index of investment-grade corporate fixed-rate debt issues with maturities of one year or more.

Bloomberg Barclays U.S. Corporate High Yield Index is an unmanaged index that is comprised of issues that meet the following criteria: at least $150 million par value outstanding, maximum credit rating of Ba1 (including defaulted issues), and at least 1 year to maturity.

ICE BofAML High Yield US Emerging Markets Corporate Plus Index tracks the performance of US dollar denominated below investment grade emerging markets corporate debt publicly issued in the US domestic or eurobond market.

The Palmer Square CLO Debt Index is designed to reflect the investable universe of US CLO mezzanine original rated A, BBB and BB debt issued after Jan 1, 2011.

S&P Leveraged Loan Indexes (S&P LL indexes) are capitalization-weighted syndicated loan indexes based upon market weightings, spreads, and interest payments. The S&P/LSTA Leveraged Loan 100 Index (LL100) dates back to 2002 and is a daily tradable index for the U.S. market that seeks to mirror the market-weighted performance of the largest institutional leveraged loans, as determined by criteria. Its ticker on Bloomberg is SPBDLLB.
For More Information

New York Headquarters
400 Park Avenue
New York, NY 10022
212-702-3500

Beverly Hills Headquarters
400 North Roxbury Drive
Beverly Hills, CA 90210
310-888-6000

info@cnr.com
www.cnr.com